Shared Decision-Making With Physicians Helps Assess, Improve Pain

Article

Shared decision-making with health care providers can help to implement a comprehensive pain assessment at baseline and improve outcomes among patients with metastatic cancer.

Shared decision-making with health care providers can help to implement a comprehensive pain assessment at baseline and improve outcomes among patients with metastatic cancer, according to study results presented at the ONS 44th Annual Congress.

“Shared decision making can foster earlier identification and improved pain management, where patient preferences, goals, and concerns are discussed,” Jeannine Brant Ph. D., APRN, AOCN, FAAN, Billings Clinic, said during her presentation.

The prevalence of cancer pain ranges from 52% to 77%, which contributes to suffering and increased health care utilization, she added.

Therefore, in one of the first studies to examine shared decision-making as part of the pain management plan of care, 52 patients with metastatic cancer experiencing pain or were taking opioids to manage chronic cancer pain completed a tablet-based survey at enrollment to record baseline pain and activity levels, pain flare severity and length, end of dose pain and shared decision-making preferences.

In turn, results from the survey were then presented on an electronic dashboard and the healthcare provider and patient collaboratively established a pain care plan. The tailored care plans defined the breakthrough agent for treatment, reinforced the patient taking a long-acting opioid and provided specific medication instructions, Brant explained. Next, in visits two through four, the health care providers tracked symptoms over time to determine if they were making any progress with patient pain.

The effectiveness of shared decision-making on pain outcomes was then measured with the Pain Care Quality Survey. “This really addresses who well we take care of their pain needs as well as involving them in decision making in the pain care plan,” Brant said.

The majority of patients were female (63%) and white (61%), at a mean age of 56. Diagnoses included breast (nine patients), hematologic (seven patients), gastrointestinal (seven patients), gynecologic (six patients), head and neck (six patients), endocrine (six patients), thoracic (five patients), colorectal (three patients) and other types of cancer (six patients).

At baseline, the average pain scores was 6.0 on a scale from zero to 10, which improved to 5.0 at the second visit. In total, 88% reported to have experienced pain flare, with a mean severity score of 8.0, of which 74% said their flares last longer than 30 minutes. In addition, 70% reported experiencing unexpected pain and 25% had end-of-dose pain.

Overall, 23 patients (44%) reported a desire for shared decision-making with their provider, while 22 (42%) preferred to make their final decision after they consider their health care provider’s input and five patients (10%) wanted to leave the decision up to their physician.

“Patients were pretty satisfied with the platform and we’ve been doing these for quite some time now,” Brant said.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content